Johnson & Johnson $JNJ Position Reduced by Resources Management Corp CT ADV

Key Points

• Resources Management Corp CT ADV has reduced its stake in Johnson & Johnson by 8.4%, selling 6,500 shares, which now represents 1.6% of its total portfolio.
• Johnson & Johnson's EVP, Jennifer L. Taubert, sold 56,471 shares for over $10 million, resulting in a 24.08% decrease in her position.
• The company recently declared a quarterly dividend of $1.30 per share, yielding 2.9%, with an annualized payout of $5.20.

Resources Management Corp CT ADV trimmed its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 8.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 70,538 shares of the company's stock after selling 6,500 shares during the quarter. Johnson & Johnson makes up 1.6% of Resources Management Corp CT ADV's portfolio, making the stock its 14th biggest position. Resources Management Corp CT ADV's holdings in Johnson & Johnson were worth $11,698,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently added to or reduced their stakes in JNJ. Highline Wealth Partners LLC boosted its stake in Johnson & Johnson by 51.8% during the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after acquiring an additional 86 shares during the last quarter. Stone House Investment Management LLC bought a new position in shares of Johnson & Johnson in the 1st quarter worth about $47,000. 1248 Management LLC bought a new position in shares of Johnson & Johnson in the 1st quarter worth about $48,000. von Borstel & Associates Inc. bought a new position in shares of Johnson & Johnson in the 1st quarter worth about $49,000. Finally, Capital A Wealth Management LLC bought a new position in shares of Johnson & Johnson in the 4th quarter worth about $50,000. 69.55% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the firm's stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 0.16% of the company's stock.

Johnson & Johnson Stock Down 0.3%

Johnson & Johnson stock opened at $178.20 on Friday. The stock has a market cap of $429.15 billion, a price-to-earnings ratio of 19.06, a PEG ratio of 2.27 and a beta of 0.40. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The company's 50-day moving average price is $168.57 and its two-hundred day moving average price is $160.78. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $181.16.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm had revenue of $23.74 billion for the quarter, compared to analysts' expectations of $22.85 billion. During the same quarter last year, the company earned $2.82 EPS. Johnson & Johnson's quarterly revenue was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be given a dividend of $1.30 per share. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 2.9%. Johnson & Johnson's dividend payout ratio (DPR) is 55.61%.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on JNJ. Leerink Partners downgraded shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and reduced their price target for the stock from $169.00 to $153.00 in a research report on Tuesday, May 13th. Erste Group Bank upgraded shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Wednesday, July 23rd. Bank of America increased their price objective on shares of Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a report on Thursday, July 17th. Morgan Stanley increased their price objective on shares of Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a report on Thursday, July 17th. Finally, Royal Bank Of Canada increased their price objective on shares of Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a report on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $176.29.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.